Fig. 4

NOX1 inhibition does not prevent HCC development in mice. In order to induce HCC, mice received weekly DEN (35 mg/kg) injections for 25 weeks. At week 15, mice were treated daily with vehicle or 30 mg/kg of GKT771 for 15 weeks via oral gavage. At week 30 of the experiment, mice were sacrificed. a Body, liver and spleen weight were recorded and b macroscopically visible tumors were counted. NOX1 inhibition attenuates the Induction of hepatic cancer stem cell markers in DEN-induced HCC. c The mRNA expression of HCC (AFP and GP3) and cancer stem cell (MDR1, EPCAM, CD44, CD133) markers in the separated tumoral lesions and non-tumoral surrounding liver tissue of both vehicle and GKT771 treated HCC mice was evaluated by RT-qPCR. ^nsnot significant; * p < 0,05; ** p < 0,01; *** p < 0,001; **** p < 0,0001 compared to vehicle-treated healthy controls, unless indicated differently